WHOOP CEO, Will Ahmed: 50B Hours of Health Data, a 4 Million Member Data Moat, & the FDA Fight

Summary

• WHOOP’s accelerating membership growth makes retention and recurring revenue the central business story. Ahmed says reaching one million members took 12 years, two million another 18 months, and three million another six months; he expects around four million at year-end. Replacing a $500 purchase with subscriptions now priced at $15–$30 monthly lowered the entry barrier and made WHOOP “really obsessed with” existing members.
• WHOOP’s data advantage combines continuous measurement with context for interpreting it. Members wear the device 23.6 hours daily, generating just over 50 billion hours of physiological data; blood tests, medical records, and journal feedback add context. Ahmed says WHOOP is developing its own foundational models, but biomarker prediction remains preliminary: physiological signals “might” identify an abnormal result without directly measuring it. He also says 80% of members interact with the AI.
• Personalized coaching is already useful, while the journal’s examples show why correlation needs scrutiny. Jason reports an apparent 7% recovery benefit associated with warm baths, but his apparent 3% penalty from vitamin D prompts questions about travel and missing observations. The assistant describes that result as “a correlation, not evidence”; the newer GLP-1 tracker turns personal context into activity, hydration, and protein goals.
• The FDA dispute centers on whether blood pressure can serve wellness purposes without a medical diagnosis. Ahmed says WHOOP received a warning letter, maintained its position, and kept Blood Pressure Insights available after guidelines changed. He thinks WHOOP’s case helped drive that change; its ECG feature separately has FDA 510(k) clearance.
• WHOOP’s expansion strategy favors controlling the health experience while replacing some adjacent hardware. Jason proposes branded cuffs and scales, citing a $10 billion valuation and illustrative revenue arithmetic of four million members paying $250 annually. Ahmed calls cuffs commoditized and says the longer-term ambition is to “replace the cuff”; he also says WHOOP does not sell member data.
• LeBron James’s ambassador deal formalizes an existing customer relationship rather than creating one. Ahmed says James has worn WHOOP for 11 years and was among its first 100 users. The original principle still matters: “you want people to love your product authentically.” Some athletes later invested, and WHOOP developed name, image, and likeness agreements.
• The closing discussion flags company approval and broker claims as checks in private-market secondaries. Ahmed advises building a relationship with the company CFO and getting their blessing for an SPV or secondary transaction. Jason says some brokers claiming to have shares are “trying to create a market”; Ahmed describes his own inquiries going quiet when he asks for details.

Deep dive

1. Subscriptions changed WHOOP’s growth curve and incentives

• Founded in 2012, WHOOP took roughly 12 years to reach one million members, another 18 months to reach two million, and another six months to reach three million. Ahmed expects around four million at year-end. The company now employs 1,200 people: an “overnight success” that took a long time.

• The consumer product launched in 2017 at $500 upfront. Over the following year, Ahmed observed unusually persistent usage but insufficient purchases. The subscription experiment addressed that mismatch: lower the entry price, let customers discover the value, and earn revenue over time. He credits the change with growth in 2018–19; current plans range from $15 to $30 monthly.

• The deeper change was organizational. Subscriptions made WHOOP “really obsessed with” existing members, engagement, effectiveness, and behavior change. Ahmed contrasts that with hardware businesses needing another sale every 12 months: WHOOP wants new hardware when it is “a step function better,” while continually improving products already in members’ hands.

• That commitment extends beyond the original purchase proposition. Ahmed lists ECG monitoring, AFib detection, Advanced Labs blood testing, the Healthspan longevity feature and WHOOP age, and Blood Pressure Insights as capabilities members might not have anticipated 18 months earlier. Jason’s endorsement is that WHOOP assumes responsibility for explaining when an upgrade is worthwhile.

2. Continuous baselines make small physiological changes visible

• WHOOP organizes its interface around sleep, recovery, and strain; recovery becomes a red, yellow, or green score from 0–100%. Continuous measurement shapes the hardware: a 14-day battery and a charger that slides onto the device during wear. Ahmed says members consequently wear WHOOP an average of 23.6 hours daily.

• Ahmed describes heart rate variability as a lens into autonomic regulation, with sympathetic and parasympathetic activity working together. His typical age benchmarks fall from 80–100 in one’s 20s to around 70 in the 30s, 50 in the 40s, and 30 or below in the 50s and 60s. Keeping HRV flat over years, he argues, can itself indicate good fitness and longevity.

• Jason’s example is an early warning rather than a specific diagnosis. His respiratory rate rose about two breaths above normal and skin temperature about 2° for two consecutive days before Sunday-night chest pain sent him to the emergency room. He says testing found inflammation rather than a heart attack; the earlier readings had put him “on high alert.”

• Ahmed recalls another member with close to a decade of baseline data whose HRV fell from about 100 to 50. Subsequent medical testing found testicular cancer. Jason asks whether HRV was previously known as a leading indicator for that cancer. Ahmed’s answer preserves the uncertainty: “I don’t think so.”

3. The AI opportunity depends on combining different kinds of data

• Continuous wear has produced just over 50 billion hours of physiological data, which Ahmed calls “one of the largest health data sets in the world.” WHOOP is developing its own foundational models and combining sensor information with uploaded blood tests, Advanced Labs results, and medical records.

• Ahmed says WHOOP is “starting to see indications” that physiological signals “might” predict whether a biomarker is out of range without measuring that biomarker directly. His hypothetical next step is a targeted recommendation to test cortisol.

• Self-reported context supplies another layer. Just over 50% of members journal daily across more than 100 behaviors, supplements, drugs, and lifestyle choices. Mood entries could, for example, supply information for predicting happiness. Ahmed also cites members opening the app eight times daily and 80% of the membership interacting with the AI.

• Jason’s assessment of the coach has changed: initially “pretty dumb,” it now earns seven and a half out of 10. He describes receiving flight-specific advice about sleep and caffeine when traveling to Japan. Asked whether the system inferred that capability independently, Ahmed explains that WHOOP created a dedicated travel team because the use case was so popular.

4. Journaling turns personal observations into coaching, with confounding still visible

• Jason thinks behavioral insights become available after five “yes” and five “no” entries. He reports an apparent 7% recovery improvement associated with warm baths and a –9% association for alcohol. Ahmed says alcohol has a hugely negative effect for many people. He also says eating within three hours of bedtime is detrimental across the WHOOP population, explaining that digestion interferes with quality sleep during the first hours in bed.

• Jason challenges his apparent 3% recovery penalty from vitamin D: “I don’t know if that’s accurate or not.” Ahmed suggests travel might explain the association. The coach adds that Jason has not logged vitamin D during the latest 14-day stretch and calls the result “a correlation, not evidence” of causation.

• GLP-1 tracking adds medication context to the same coaching system. Ahmed says that typically about half the weight lost is fat and half muscle, making strength work and protein priorities in WHOOP’s response. He describes reports of creatine helping as “anecdotal success,” while emphasizing activity—even bodyweight training—to limit muscle loss.

• Jason says he lost 43 pounds, moving from 213 to 170, and now takes a maintenance dose. His agreed plan includes 9,800 steps, two strength activities weekly, daily hydration, protein, and logging his GLP-1 dose. Ahmed checks that the AI discussed the plan and Jason confirmed the goals, illustrating how the assistant translates personal circumstances into commitments.

5. The FDA fight challenged a boundary between wellness and medicine

• Ahmed says WHOOP began pursuing wrist-based blood pressure monitoring four years earlier. A stress, sleep, and blood pressure study enrolled 70,000 people, with participants uploading cuff readings daily over several weeks. Pairing those readings with existing physiology created training data. WHOOP’s stated ambition was accuracy “as accurately—or within similar accuracy—as a medical device.”

• His regulatory argument concerns intended use. Heart rate monitoring for exercise or sleep falls under wellness, while AFib detection or heart attack prediction requires medical regulation. Blood pressure, he says, historically faced a blanket medical-device requirement. WHOOP believed research connecting blood pressure with stress, sleep, and well-being justified a corresponding wellness application.

• WHOOP launched Blood Pressure Insights and received an FDA warning letter. Ahmed says the company “stuck to our guns” through a public disagreement. He reports that the FDA subsequently updated guidelines to recognize blood pressure wellness applications, “I think based on our case” and industry feedback. The feature remains available; he describes the current FDA relationship as positive.

• Ahmed distinguishes that dispute from WHOOP’s regulated products. Its wrist ECG feature has FDA 510(k) clearance. Depending on the application, WHOOP either pursues clinical trials and medical clearance or seeks a faster wellness launch. His position is that both approaches belong in an innovative company’s relationship with the agency.

6. WHOOP wants control of the experience without making every accessory

• Jason asks for WHOOP-branded scales and cuffs, citing a $10 billion valuation and estimating $1 billion revenue from four million members paying $250 annually. Those figures come from the host’s framing. Ahmed says WHOOP often favors building or acquiring over partnering, but regards cuffs as commoditized technology: people can calibrate WHOOP with a cuff, after which WHOOP can measure blood pressure without one. “At the end of the day, we kind of want to replace the cuff.”

• Ahmed links the right to accumulate health information to strong data policies: “we do not sell data,” and “you are not the product, Jason.” He also resists Jason’s dismissal of Apple, calling its watch the most successful smartwatch and respecting its hardware and software. He notes that the wearables field had more competing products 10 years earlier than today.

7. Athlete marketing follows authentic adoption, while access rules lag

• LeBron James is becoming a global ambassador after 11 years wearing WHOOP without a formal relationship. Ahmed says James was among the first 100 users, making his adoption unusually validating for an unknown company. He joins an ambassador roster that includes Cristiano Ronaldo, Patrick Mahomes, and Lewis Hamilton.

• Jason presses whether paid partnerships reverse WHOOP’s earlier reluctance to pay athletes to wear the product. Ahmed says companies not yet doing large-scale advertising should be careful about paying people to use their products. “You want people to love your product authentically”; because WHOOP must be worn 24/7, he says, paying an athlete who dislikes it would not work. Some athletes later invested, and WHOOP developed name, image, and likeness agreements to advertise those relationships.

• Competition access remains unsettled: Ahmed says NBA game usage is still under review. At the Australian Open, players were asked to remove WHOOP despite International Tennis Federation approval, while other majors subsequently said wearables could be worn. Ahmed describes a “natural evolution” toward acceptance. Jason instead suspects sponsorship pressure, joking that a $10 million advertising commitment might change organizers’ opinions.

8. Secondary-market demand creates another verification problem

• Jason says he started a late-stage practice after members of his 4,000-member syndicate asked for access to later-stage companies, with deals including Zipline and ICON Homes. He notes that when he knows a founder, the CFO approves transactions. Ahmed advises building a relationship with the company’s CFO, getting their blessing, and accepting a refusal.

• Jason says some secondary brokers claiming to have shares are “really just trying to create a market.” Ahmed describes his own experience: brokers claim to have shares at a certain price, but when he asks who the transaction is with and offers to coordinate with the company CFO, they go quiet. He calls it a “fishing expedition” and says these situations arise when a company is doing well as well as when it is failing.